This was recently posted on the Yahoo board by a user named

New Post Public Reply Private Reply Replies (0) Message Board
blafarm
1,192
This was recently posted on the Yahoo board by a user named King James XIV.

Very important:

I'm not re-posting here because I believe this thesis, especially since I have significant doubt regarding Trumps statements being related to leronlimab.

I am simply reporting on activity on another board.

Quote:
King James XIV4

I was golfing yesterday, but could not get the Trump/Leronlimab puzzle off my mind! I really enjoy these mysteries so decided to recap of what we know for newbies. After reviewing, I have upped my odds that he is talking about Leronlimab to 70%.

Bread Crumbs

1. Trump Press conference, paraphrasing,,"we are doing very well with therapeutics, you go into a hospital, get a SHOT and feel better".
2. Trump call in to Hannity show to mention SHOT in a similar way.
3. Trump press conference a few weeks back when he says "we are looking at an Aids Vaccine" which was later corrected by his staff to be a therapeutic (like Leron)
4. Fauci has said multiple times the a bridge might be a subcontaneous shot of monoclonal antibodies
5, Small one..but Dr. Paterson said he has been in talks with Barda and that Leronlimab would be a drug to stockpile.
6. It is probable, imho, the FDA has seen some of the data from the m/m study and know it is better than Remdesivir. They definitely have seen data from the s/c phase 3 trial. If death can be taken off the table in a meaningful way, that is a big win.

Could he be referring to one of our competitors?

1. Tocilizumab - IV treatment. Pretty nasy side effects possible. Severe infections. NO.
2. Lenzilumab - HGEN - Phase 3 trial. But this is one hour IV infusion, every 8 hours for three courses.
3. Itolizumab - This is the one that was approved in India. It is injectable, but studies have not been done in the US yet. Certainly possible Trump was talking about this, but the data just isn't there yet. I would say unlikely.
My Comment: See this recent update where the COVID-19 Task Force is now not in favor of itolizumab for treatment.
https://www.newindianexpress.com/nation/2020/...74698.html

4. Remestemcel-L - This is adminsterd via an IV, so don't think it is this.
5 REGN COV2 - Looks like they are in Phase 3? Data expected by end of summer? Looks like the monoclonal antibody adheres to the virus and prevents it from spreading. Don't know how admined.
6. Eli Lilly - They have something but appears to be ways away.
7. Galidesivir - No data out soon. It is in P1 trials in Brazil, and requires IV TWICE every day for seven days MINIMUM.... from the trial description. After treatment, the patients will remain hospitalized until resolution of symptoms allows release. All patients will be followed for mortality through Day 56. Sounds like this is a long way away.
8.Eiger Pharma - Looks like their Peginterferon Lambda is in Phase 2 of about 100 patients with mild sympoms that are hospitalized.. Looks like it is an injection.
9. Plasma Therapy - Can't scale and not a shot

Anything big pharma related is a real competitor, but I think REGN COV2 is the biggest competitor, because they love Regeneron.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DayOne's Bold Energy Moves With Sembcorp for Asia Growth

Updated Category News Views 79

It seems the digital world and power supply have locked in a new dance as DayOne Data Centers teams up with Sembcorp Utilities. It's high time we gave this story a solid look, especially with data centers gobbling energy faster than my old trading partner downs an espresso. Tackling Energy Constraints Head-On The digital infrastructure beast is hungry for power, and...

Continue Reading
Jack Henry's Q1 2027 Deconversion Revenue Hits $17.9M

Updated Category News Views 30

Jack Henry Surprises with Strong Deconversion Revenue You're probably thinking, deconversion revenue—what on earth is that? Imagine you're in the financial tech business and one of your bigwig clients decides to merge or get gobbled up by another institution. They move shop, and voila, you've got some unexpected money flowing in due to that exit. That's deconversion...

Continue Reading
Young Leaders Drive Be Strong’s Mental Health Movement

Updated Category News Views 50

New Voices at the Helm Today’s youth aren’t just tomorrow's leaders; they’re stepping up now. Groups like Be Strong’s newly minted National Student Advisory Board are proving that. Sixteen kids across eleven states are diving headfirst into transforming mental health narratives. This ain't just some school club. These young guns are gearing up to reshape how we...

Continue Reading
Spotting Alzheimer's: Holiday Visits Might Reveal More

Updated Category News Views 34

The Unspoken Truth of Holiday Reunions Is there any better barometer than a holiday visit to gauge how your parents are truly doing? Most of us are zooming in, lugging our baggage through the front door and finding Dad telling the same old story not once, not twice, but three solid times at the table. Then there’s Mom, fumbling her way through that pie recipe she could...

Continue Reading
Yale's $10M Inflammation Initiative: Future Health Impact

Updated Category News Views 45

Yale’s Inflammation Research: Beyond the Basics Inflammation. It’s the kind of battle your own body wages from within, and Yale School of Medicine’s fresh $10 million grant from the Blavatnik Family Foundation means they’re marching deeper into the trenches. This is not another academic exercise; it’s about digging out the roots of diseases that are tough to pin...

Continue Reading
CloudKeeper Simplifies AI Cost Tracking with FinOps Launch

Updated Category News Views 43

AI Cost Management: A Complex Endeavor Tracking the myriad costs of AI operations can be downright infuriating. Every company dipping its toes in these waters quickly finds itself tangled in a web of fees spanning different models, applications, and cloud services. This tangled mess is about to get some much-needed untangling, thanks to CloudKeeper's latest move. They're...

Continue Reading
Quanta Services Reports Record Q3 2026 Earnings

Updated Category News Views 79

Quanta Services Smashes Q3 2026 Expectations If you're a stakeholder in Quanta Services, you'd probably be dancing in the aisles right now. This company just posted off-the-charts numbers for the third quarter of 2026. We're talking revenues of $12 billion—a staggering leap from $7.63 billion the same quarter last year. Explosive Earnings and Strong Backlog The star of...

Continue Reading
Wabi's $1.25B Valuation: A New Era for AI?

Updated Category News Views 155

A Major Milestone for Wabi Well, here we go—Wabi, the brainchild of Eugenia Kuyda, is stirring the pot with a massive $55 million funding round, pulling its valuation up to a hefty $1.25 billion. If you're raising eyebrows at that price tag, you’re not alone. It's a big number riding on an even bigger idea: that AI isn't just for solitary chats anymore, but for...

Continue Reading
ACTEC Welcomes 55 New Fellows: A Closer Look

Updated Category News Views 99

Coffee's brewing hot, and so are the stakes at ACTEC, where 55 new Fellows just got the nod. The American College of Trust and Estate Counsel isn't your average club. They've been at this game since 1949, bringing together the finest minds in trusts and estates. But what does this newest batch bring to the table, and why should investors take a moment to notice? A Diverse...

Continue Reading
Static Media Acquires CarScoops to Boost Auto Reach

Updated Category News Views 74

Static Media's Latest Move in the Automotive Arena The digital media landscape keeps morphing, and Static Media just decided to crank up the gears a notch by snapping up CarScoops.com. For those with an eye on the automotive field, it's the kind of play that could shift the tides. Static Media, already a heavyweight with brands like Jalopnik and SlashGear under its belt,...

Continue Reading

Top 5 Most Recently Viewed Articles

Legal Action Against Jetstar for Misleading Passenger Rights

Updated Category News Views 207

Legal Action Against Jetstar for Misleading Passenger Rights New Zealand's competition authority is taking serious action against Jetstar, a low-cost airline operating under Qantas. They're in court over allegations that Jetstar misled its passengers about their rights to compensation due to delayed and cancelled flights. Allegations of Misleading Practices The New...

Continue Reading
Loona Petbot Commemorates Anniversary with User Engagement Surge

Updated Category News Views 197

Loona Petbot Commemorates Anniversary with Impressive User Engagement KEYi Technology is excited to share the remarkable success of its 1000-day anniversary celebration of the Loona Petbot. This event commenced recently and received an overwhelming response from users around the world. More than ten thousand participants engaged in the celebrations, showcasing the growing...

Continue Reading
Exploring Royce Small-Cap Trust: Current Insights and Trends

Updated Category News Views 145

Introduction to Royce Small-Cap Trust Royce Small-Cap Trust (NYSE: RVT) stands as a prominent name in the small-cap investment landscape, renowned for its commitment to long-term capital growth. Established as one of the oldest and largest closed-end funds focused on small-cap and micro-cap securities, this trust has carved a niche for itself among investors seeking...

Continue Reading
Grace Hill Teams with IWBI to Advance WELL Workspaces

Updated Category News Views 8

Pushing the Boundaries of Building Health The workplace is evolving, pal, and it ain't the stodgy cubicle farm it once was. Grace Hill, the technological maestro of real estate performance solutions, has shaken hands with the International WELL Building Institute (IWBI). This move ain't just about pushing a few papers but about bringing the occupant experience front and...

Continue Reading
Oppenheimer Upholds Outperform Rating for Tarsus Pharmaceuticals

Updated Category News Views 63

Oppenheimer Reaffirms Positive Outlook on Tarsus Pharmaceuticals Recently, Oppenheimer reiterated its favorable stance on Tarsus Pharmaceuticals (NASDAQ:TARS), affirming an Outperform rating coupled with a price target of $63. This endorsement comes ahead of the company's anticipated financial report for the third quarter of 2024, with special attention on the performance...

Continue Reading